Keywords: Apricus Bio, Stellar Pharma, MycoVa, License, Canada, Nail fungus
Stellar Pharma to sell Apricus MycoVa in Canada
Article | 04 January 2012
USA-based Apricus Biosciences (Nasdaq: ARI) has signed an exclusive license agreement with Canada’s Stellar Pharmaceuticals (OTCQB: SLXCF) whereby ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
